Synergistic Effects of Thymosin Alpha-1, BPC-157, TB-500, LL-37, MOTS-c, SS-31, CJC-1295 with DAC, Ipamorelin, and Nicotine on Lyme Disease Reversal in a Borrelia burgdorferi-Infected Murine Model.docx
physician_protocol · expert_opinion · status: needs_provider_review
Metadata
Summary (generated — provider review required)
UPDATED Synergistic Effects of Thymosin Alpha-1, BPC-157, TB-500, LL-37, MOTS-c, SS-31, CJC-1295 with DAC, Ipamorelin, and Nicotine on Lyme Disease Reversal in a Borrelia burgdorferi-Infected Murine Model Abstract - Read the highlighted areas for the solution !!!! This study evaluates the combined administration of Thymosin Alpha-1 (1.5 mg three times a week subcutaneously), BPC-157 (1 mg daily subcutaneously), TB-500 (5 mg every five days subcutaneously), LL-37 (200 mcg daily subcutaneously), MOTS-c (3 mg three times a week subcutaneously), SS-31 (2 mg daily subcutaneously), CJC-1295 with DAC (1 mg per week subcutaneously), Ipamorelin (250 mcg nightly subcutaneously), and Nicotine (7 mg daily transdermal patch) on Lyme disease reversal in Borrelia burgdorferi-infected adult male C57BL/6 mice over a 12-week period. Primary outcomes included bacterial clearance (qPCR for Borrelia DNA in joints, heart, and bladder) and joint inflammation resolution (histological arthritis score).
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (11) · phenotypes (3)
dosing_reference, mechanism, safety_reference, evidence_reference
Phenotypes: neuroinflammation, immune_dysregulation, mitochondrial_dysfunction
Evidence claims (37) · review items (27)
dosing · pending
This study evaluates the combined administration of Thymosin Alpha-1 (1.5 mg three times a week subcutaneously), BPC-157 (1 mg daily subcutaneously), TB-500 (5 mg every five days subcutaneously), LL-37 (200 mcg daily subcutaneously), MOTS-c (3 mg three times a week subcutaneously), SS-31 (2 mg daily subcutaneously), CJC-1295 with DAC (1 mg per week subcutaneously), Ipamorelin (250 mcg nightly subcutaneously), and Nicotine (7 mg daily transdermal patch) on Lyme disease reversal in Borrelia burgdorferi-infected adult male C57BL/6 mice over a 12-week period.
outcome · pending
Primary outcomes included bacterial clearance (qPCR for Borrelia DNA in joints, heart, and bladder) and joint inflammation resolution (histological arthritis score).
mechanism · pending
Secondary measures encompassed neuroinflammation (brain TNF-α/IL-6 ELISA), oxidative stress (ROS/MDA levels), mitochondrial ATP production (luminescence assay), immune modulation (splenic CD4+/CD8+ ratio via flow cytometry), and physical performance (grip strength as frailty surrogate).
outcome · pending
The combination reduced Borrelia load by 70%, arthritis score by 65%, neuroinflammation by 55%, oxidative stress by 50%, enhanced ATP production by 45%, normalized immune ratios, and improved grip strength by 40% compared to infected controls.
safety · pending
No adverse effects were observed.
outcome · pending
BPC-157 promotes tissue repair and reduces inflammation in Lyme arthritis models.
outcome · pending
MOTS-c improves mitochondrial function in inflammatory models.
outcome · pending
SS-31 protects mitochondria and reduces ROS in infection-induced stress.
mechanism · pending
Nicotine modulates cholinergic anti-inflammatory pathways in infectious inflammation.
regulatory · pending
Approved by the Institutional Animal Care and Use Committee (IACUC) under protocol #2026-MUR-038, complying with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and EU Directive 2010/63/EU.
dosing · pending
Lyme disease induced by subcutaneous Borrelia burgdorferi (strain B31, 10^5 spirochetes).
dosing · pending
GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Compound Administration Compounds (>98% purity, Elitebiogenix) Thymosin Alpha-1: 1.5 mg three times a week subcutaneously (e.g., Mon/Wed/Fri, 8 AM).
dosing · pending
BPC-157: 1 mg daily subcutaneously (8 AM).
dosing · pending
TB-500: 5 mg every five days subcutaneously (8 AM).
dosing · pending
LL-37: 200 mcg daily subcutaneously (8 AM).
dosing · pending
MOTS-c: 3 mg three times a week subcutaneously (e.g., Mon/Wed/Fri, 8 AM).
dosing · pending
SS-31: 2 mg daily subcutaneously (8 AM).
dosing · pending
CJC-1295 with DAC: 1 mg per week subcutaneously (Mondays, 8 AM).
dosing · pending
Ipamorelin: 250 mcg nightly subcutaneously (8 PM).
dosing · pending
Nicotine: 7 mg daily transdermal patch (applied 8 AM, changed every 24 hours).
dosing · pending
Glutathione: 500 mg three times a week subcutaneously (e.g., Mon/Wed/Fri, 8 AM) Nutrient Protocol Magnesium Bisglycinate: 600 mg daily (PM0 Zinc: 30 mg daily Methylated B Complex D3: 5000 IU (taken with K2) daily K2: 200 mcg (taken with D3) daily Ubiquinol: 200 mg daily Treatment lasted 6 months Outcome Measures Bacterial Clearance: qPCR for Borrelia DNA in joints, heart, bladder at endpoint.
mechanism · pending
Immune Modulation: Splenic CD4+/CD8+ ratio (flow cytometry) endpoint.
safety · pending
Results Survival 100%; no toxicity.
mechanism · pending
Borrelia DNA (Log Copies/g, Joint) Arthritis Score (0-4) Control 5.5 ± 0.4 3.5 ± 0.4 Individual (Avg) 3.0 ± 0.3 2.0 ± 0.2 Combination 1.6 ± 0.2 1.2 ± 0.2 Mitochondrial ATP Production and Immune Modulation ATP +45% (p<0.001).
outcome · pending
GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Discussion The protocol achieved complete Lyme reversal: Thymosin Alpha-1/LL-37 enhanced immunity/antimicrobial effects, BPC-157/TB-500/GHK-Cu repaired tissue, MOTS-c/SS-31 supported mitochondria, CJC-1295/Ipamorelin optimized GH, Nicotine reduced inflammation.
dosing · pending
Daily/Weekly Schedule Nicotine: 7 mg patch daily (apply morning, change daily; rotate sites).
dosing · pending
BPC-157: 1 mg s.c.
dosing · pending
TB-500: 5 mg s.c.
dosing · pending
LL-37: 200 mcg s.c.
dosing · pending
MOTS-c: 3 mg s.c.
dosing · pending
SS-31: 2 mg s.c.
dosing · pending
CJC-1295 with DAC: 1 mg s.c.
dosing · pending
Ipamorelin: 250 mcg s.c.
dosing · pending
Thymosin Alpha-1: 1.5 mg s.c.
dosing · pending
Glutathione: 500 mg three times a week subcutaneously (e.g., Mon/Wed/Fri, 8 AM)
dosing · pending
Nutrient Protocol Magnesium Bisglycinate: 600 mg daily (PM0 Zinc: 30 mg daily Methylated B Complex D3: 5000 IU (taken with K2) daily K2: 200 mcg (taken with D3) daily Ubiquinol: 200 mg daily GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Monitoring Daily: Symptom diary (pain/fatigue 0-10).
safety · pending
Goal: Zero symptoms, negative tests within 6 months Safety Mild reactions possible (injection sites).
Extracted chunks (8)
1057 approx tokens across 8 chunks.